Durham pharma could be on its way to second FDA approval

Durham-based Aerie Pharmaceuticals (Nasdaq: AERI) could be well on its way to a second U.S. Food and Drug Administration approval.   The FDA has accepted Aerie’s new drug application (NDA) submission for the company’s second glaucoma drug, Roclatan, earlier than expected.  Aerie said this week that the FDA has set a goal date for completion of the agency’s review of the Roclatan NDA of March 14, 2019. The NDA acceptan ce comes less than three months after Aerie said it had launched its first…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news